Premium
Time‐Dependent Interaction Between Lopinavir/Ritonavir and Fexofenadine
Author(s) -
Rolf P. G.,
Heeswijk van,
Bourbeau Marc,
Campbell Pearl,
Seguin Isabelle,
Chauhan Bobby M.,
Foster Brian C.,
Cameron D. William
Publication year - 2006
Publication title -
the journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.92
H-Index - 116
eISSN - 1552-4604
pISSN - 0091-2700
DOI - 10.1177/0091270006288733
Subject(s) - lopinavir , ritonavir , fexofenadine , lopinavir/ritonavir , pharmacology , pharmacokinetics , medicine , bioavailability , chemistry , immunology , viral load , human immunodeficiency virus (hiv) , covid-19 , antiretroviral therapy , disease , infectious disease (medical specialty)
This study investigated the effect of single‐dose and steady‐state lopinavir/ritonavir on the exposure to fexofenadine, as a measure of P‐glycoprotein activity. Sixteen volunteers (8 women) received single‐dose oral fexofenadine 120 mg alone, in combination with single‐dose ritonavir 100 mg or lopinavir/ritonavir 400/100 mg (randomized 1:1, stratified by sex), and in combination with steady‐state lopinavir/ritonavir 400/100 mg twice daily. Single‐dose ritonavir and lopinavir/ritonavir increased the area under the fexofenadine plasma concentration‐time curve from 0 to infinity (AUC ∞ ) by 2.2‐ and 4.0‐fold, respectively ( P < .02). Steady‐state lopinavir/ritonavir increased the fexofenadine AUC ∞ by 2.9‐fold. No changes were observed in the fexofenadine elimination half‐life ( P > .12). The fexofenadine AUC ∞ was increased by lopinavir/ritonavir, likely due to increased bioavailability secondary to P‐glycoprotein inhibition. After repeated administration of lopinavir/ritonavir, the interaction was attenuated compared to the single‐dose effect, although a net inhibitory effect was maintained. Time‐dependent inhibition of P‐glycoprotein by lopinavir/ritonavir should be considered when P‐glycoprotein substrates are coadministered.